Dr. Pedro R. Moreno performs over one thousand cardiac coronary invasive procedures annually (including diagnostic catheterizations, angioplasties and coronary stents) with >99% success rate and <1% major complications. Trained at Harvard Medical School (Massachusetts General Hospital and Brigham and Women's Hospital), Dr. Moreno is triple board certified in Internal Medicine, Cardiology, and Interventional Cardiology. As a world-renowned expert in atherosclerosis, Dr. Moreno has been a pioneer in the understanding of inflammation and acute coronary syndromes. Dr. Moreno described for the first time the role of macrophages in living patients with unstable angina and acute myocardial infarction in 1993. Its impact in the scientific community was evident by the immediate recognition, which opened new routes of investigation around the world. Dr. Moreno identified a significant correlation between macrophages and tissue factor, a membrane-bound protein responsible for the activation of coagulation in vivo. Consequently, his studies showed the double sword of inflammation in human atherosclerosis; i.e. plaque rupture and coronary thrombosis. Dr. Moreno also contributed to vascular biologic aspects of restenosis, a renarrowing process that occurs in coronary or peripheral arteries after stenting. His work established the link between inflammation and smooth muscle cell proliferation in-vivo. These findings provided the rationale for revolutionary state of the art therapies including anti-inflammatory and anti-proliferative drug-eluting stents, currently used in daily practice around the world. In addition, Dr. Moreno integrated his observations in a major health problem in America: diabetes mellitus.

Education & experience

Education

Medical School - Pontificia Universidad Javeriana Bogotá Facultad de Medicina

Pontificia Universidad Javeriana Bogotá Facultad de Medicina, Residency in Internal Medicine

Harvard University, Brigham and Women's Hospital, Residency in Internal Medicine

Massachusetts General Hospital, Fellowship in Interventional Cardiology

Practice

Mount Sinai Cardiology

Certifications

Cardiovascular Disease (Internal Medicine)

Interventional Cardiology (Internal Medicine)

Awards and publications

Castle Connolly Top Doctor

Appointed Reviewer for PCR Annual Scientific Sessions

Levy AP, Purushothaman KR, Guetta J, Ashleh R, Moreno PR, Cohen O, Zias EA, Benhayon D, Fuster V, Marsh S. Decreased D163 expression in individuals with the Hp2-2 genotype and diabetes: Implications for plaque vulnerability. Circ Res 2007; 101: 106-110.

Levy AP, Levy JE, Kalet-Litman , Miller-Lotan R, Levy NS, Moreno PR, Guetta J, Yang C, Purushothaman KR, Fuster V, Asaf R. Haptoglobin genotype is a determinant of iron, lipid peroxidation and macrophage accumulation in the atherosclerotic plaque. Arteriosclerosis Thromb Vasc Biol 2007; 27(1): 134-140.

Sanz J, Fuster V, Moreno PR. The year in atherothrombosis. J Am Coll Cardiol 2007; 49(16): 1740-1749.

Fuster V, Moreno PR. New Aspects in the Pathogenesis of Diabetic Atherothrombosis. JACC 2004; 44: 2293-2300.

Fuster V, Moreno PR. The Year in Atherothrombosis. JACC 2004; 44: 2099-2110.

Moreno PR, Purushothaman KR, O'Connor WN, Echeverri D, Truszczynska H, Fuster V. Tunica media and plaque neovascularization is increased in ruptured atherosclerotic lesions of the human aorta: implications for plaque vulnerability. Circulation 2004 Oct 5; 110(14): 2032-2038.

Background

Languages spoken

English

Spanish

Gender

Male

NPI number

#1861414096

Pedro R. Moreno does not participate in Zocdoc to offer online booking at this time

Search similar providers